Curated News
By: NewsRamp Editorial Staff
July 08, 2026

NanoViricides Gets Outperform Rating, Analyst Sees $6 Target

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • NanoViricides gets Outperform rating and $6 target from Noble Capital Markets, signaling potential upside for investors.
  • NanoViricides' NV-387 is a broad-spectrum antiviral that targets multiple viruses by using nanoviricide technology to disrupt viral infections.
  • NanoViricides' broad-spectrum antiviral NV-387 aims to combat resurgent infectious diseases like measles, mpox, and Ebola, improving global health.
  • NanoViricides' NV-387 is a nanoviricide that can encapsulate remdesivir, potentially creating a new COVID-19 treatment combining both drugs.

Impact - Why it Matters

This news matters because it signals growing investor confidence in NanoViricides' broad-spectrum antiviral platform, particularly NV-387, which could address multiple viral diseases including COVID-19, RSV, and emerging threats like mpox and measles. With antiviral resistance and new variants posing ongoing challenges, a successful broad-spectrum drug would be a game-changer for global health. The analyst coverage also provides independent validation of the company's potential, which may influence future funding and partnerships.

Summary

NanoViricides, Inc. (NYSE American: NNVC) has garnered fresh attention from the investment community as independent analyst Robert LeBoyer of Noble Capital Markets initiated research coverage with an “Outperform” rating and a $6.00 price target. The report highlights the company's lead broad-spectrum antiviral candidate NV-387 and its development pipeline. NanoViricides provided publicly available information and answered technical questions, but the analyst independently developed all estimates and projections. This news comes as the company continues to advance NV-387 toward Phase II human clinical trials, targeting respiratory viruses including RSV, COVID-19, Influenza, and even MPOX and Measles.

In a separate development, President and Executive Chairman Anil R. Diwan participated in a “Fireside Chat” on StockInvestor Daily’s IPO-Edge program, where he discussed the company's antiviral technology platform, regulatory progress including FDA Orphan Drug Designation, and the resurgence of infectious diseases. The company also highlighted its Rare Pediatric Disease Designation filing for measles. The NanoViricides, Inc. platform is based on the TheraCour nanomedicine technology, and the company holds exclusive licenses for multiple viral diseases. With a pipeline that includes NV-HHV-1 for Shingles and candidates for Herpes, HIV, Hepatitis, and more, NanoViricides is positioning itself as a key player in antiviral therapeutics. The company notes that drug development is lengthy and capital-intensive, and there is no assurance of success at this stage.

For investors, the latest updates are available in the company's newsroom, and MissionIR (powered by IBN) continues to provide syndicated content to enhance visibility. The full press release can be accessed at https://ibn.fm/7XBbY. As the world faces ongoing viral threats, NanoViricides' broad-spectrum approach could offer a significant advantage in combating emerging variants and neglected diseases.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Gets Outperform Rating, Analyst Sees $6 Target

blockchain registration record for this content.